Represents reimbursable costs incurred and recorded as deferred revenue on the condensed consolidated balance sheet.

No definition available.

Name:	incy_DeferredReimbursableCost
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the additional milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementAdditionalMilestonePaymentsReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the immediate milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementImmediateMilestonePaymentReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of deliverables under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementNumberOfDeliverables
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents reimbursable costs pertaining to license agreements.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementReimbursableCosts
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents reimbursed costs pertaining to research and development expenses.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementResearchAndDevelopmentReimbursedCost
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the notice period for the termination of license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementTerminationNoticePeriod
Namespace Prefix:	incy_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the upfront and immediate milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.

+ References

No definition available.

+ Details

Name:	incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix:	incy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents upper range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfRoyaltyRatePaymentsMaximum
Namespace Prefix:	incy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of royalties payable.

+ References

No definition available.

+ Details

Name:	incy_RoyaltiesPayable
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the royalty payment receivable under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_RoyaltyPaymentReceivable
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.9)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.5)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Article 5

+ Details

Name:	us-gaap_AccountsReceivableNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.

+ References

+ Details

Name:	us-gaap_ContractsRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5

+ Details

Name:	us-gaap_SalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=incy_JakaviMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=incy_LY3009104Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=incy_JAKAFIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_EliLillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseTwoAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseTwoBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License agreements (Details) $ in Thousands	1 Months Ended					3 Months Ended								12 Months Ended						73 Months Ended	74 Months Ended
License agreements (Details) $ in Thousands	Jul. 31, 2010	Jan. 31, 2010 USD ($)	Dec. 31, 2009 USD ($) item	Nov. 30, 2009 USD ($) item	Jan. 31, 2006 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)
License agreements
Research and Development Expense														$ 479,514	$ 347,523	$ 260,436
Contract revenues														77,857	104,857	91,047
Accounts receivable						$ 114,450				$ 57,933				114,450	57,933					$ 114,450	$ 114,450
Product royalty revenues														74,821	48,966	28,251
JAKAVI
License agreements
Product royalty revenues						23,600	$ 18,100	$ 17,400	$ 15,700	14,700	$ 12,100	$ 12,300	$ 9,800
Novartis
License agreements
Upfront and immediate milestone payment to be received under license agreement				$ 210,000
Product royalties in accounts receivable						23,800				14,800				23,800	14,800					23,800	23,800
Number of deliverables under license agreement \| item				2
Upfront payment received under license agreement			$ 150,000
Immediate milestone payment received under license agreement		$ 60,000
Reimbursable costs recorded as deferred revenue			$ 10,900
Reimbursable costs included in accounts receivable						300				300				300	300					300	300
Research and development expenses reimbursed														1,600	3,100	5,100
Contract revenues														65,000	92,000	78,200
Additional milestone payment received under license agreement														65,000	92,000	25,000
Novartis \| Pre-specified Events \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement				$ 1,200,000
Novartis \| Development Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone																					102,000
Novartis \| Development Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement				174,000
Novartis \| Development Milestones \| Phase Three
License agreements
Amount recognized and received for the achievement of a predefined milestone														50,000
Novartis \| Regulatory Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone																					175,000
Novartis \| Regulatory Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement				495,000
Novartis \| Commercialization Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone																					20,000
Novartis \| Commercialization Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement				$ 500,000
Novartis \| LY3009104 \| Development Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone														5,000	7,000	25,000		$ 15,000
Novartis \| JAKAVI
License agreements
Net sales														300,000
Product royalty revenues														74,800	49,000	28,300
Novartis \| JAKAVI \| Regulatory Milestones \| JAPAN
License agreements
Amount recognized and received for the achievement of a predefined milestone														15,000	25,000
Novartis \| JAKAVI \| Regulatory Milestones \| Europe
License agreements
Amount recognized and received for the achievement of a predefined milestone														25,000	60,000		$ 40,000
Novartis \| JAKAVI \| Commercialization Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone														20,000
Novartis \| JAKAFI
License agreements
Accounts receivable						20,000								20,000						20,000	20,000
Novartis \| JAKAFI \| U.S.
License agreements
Royalties Payable						$ 24,400				$ 2,200				24,400	2,200					24,400	$ 24,400
Novartis \| JAKAFI \| Regulatory Milestones \| U.S.
License agreements
Amount recognized and received for the achievement of a predefined milestone																		$ 10,000
Eli Lilly
License agreements
Number of deliverables under license agreement \| item			2
Upfront payment received under license agreement			$ 90,000
Research and Development Expense														36,000	49,300	52,400
Contract revenues														$ 12,900	$ 12,900	$ 12,900
Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop, percentage	30.00%		30.00%
Eli Lilly \| Pre-specified Events \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			$ 665,000
Eli Lilly \| Development Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone																				$ 99,000
Eli Lilly \| Development Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			150,000
Eli Lilly \| Development Milestones \| Phase Three
License agreements
Amount recognized and received for the achievement of a predefined milestone																	$ 50,000
Eli Lilly \| Development Milestones \| Phase Two A
License agreements
Amount recognized and received for the achievement of a predefined milestone																			$ 30,000
Eli Lilly \| Development Milestones \| Phase Two B
License agreements
Amount recognized and received for the achievement of a predefined milestone																			$ 19,000
Eli Lilly \| Regulatory Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			365,000
Eli Lilly \| Commercialization Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			$ 150,000
Range of royalty payments on future global net sales, upper range (as a percent)																			20.00%
Pfizer
License agreements
Upfront payment received under license agreement					$ 40,000
Period of notice for termination of license agreement					90 days
Pfizer \| Development Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement					$ 138,000
Pfizer \| Regulatory Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement					455,000
Pfizer \| Commercialization Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement					$ 150,000